1. ALLA AKTIER
  2. NYHETER
  3. PROLIGHT DIAGNOSTICS

Prolight Diagnostics

Nyheter Prolight Diagnostics Nyheter alla bolag

Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share

Read the full article here: https://www.emergers.se/prolight_e/

For further information, please contact:
Ulf Bladin, CEO
E-mail: ub@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share

Datum 2024-08-30, kl 13:48
Källa MFN
Bifogade filer
Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!